.avif)
Our Mission
Halcyon has developed a proprietary technology for the identification of novel cancer and Alzheimer's disease (AD) biomarkers, including GASP-1, which is fundamental in cancer initiation, progression, and invasion.
Our team has developed several diagnostic and therapeutic applications for the technology, which will transform cancer and AD treatment by advancing the methods for early detection in both clinical and consumer settings.
Our team has developed several diagnostic and therapeutic applications for the technology, which will transform cancer and AD treatment by advancing the methods for early detection in both clinical and consumer settings.
Neurology
The current diagnosis of Alzheimer disease (AD) is primarily based on the appearance of symptoms associated with cognitive impairment caused by aggregation of overproduced amyloid beta (Aβ) and tau protein.
Even though blood biomarkers have great promise for early detection of AD, they have proven to be challenging to incorporate into clinical practice.
Halcyon has identified several novel AD biomarkers, that are currently being tested for efficacy in an at-home setting, and a path towards direct-to-consumer test kits for the detection of AD.
Oncology
Current cancer biomarkers include those that assess DNA mutations - commonly marketed by Multi-Cancer Early Detection (MCED) companies - and abnormal expression of normal proteins.
Though many cancer detection products exist today, many are typified by limited sensitivity, significant invasiveness, and high patient cost.
Halcyon has discovered a universal cancer biomarker - GASP-1 - that is required for cancer cell growth and can be used in both a lateral flow test kit and ELISA text.
